fluorouracil has been researched along with Bone Diseases, Metabolic in 3 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Bone Diseases, Metabolic: Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A postmenopausal woman was treated for stage II breast cancer with a modified radical mastectomy and adjuvant cyclophosphamide, doxorubicin, and 5-flurouracil followed by tamoxifen for 5 years." | 3.72 | Raloxifene rebound regression. ( Dosik, M; Kaufman, R, 2004) |
| "Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0." | 1.72 | Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. ( Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Nakao, T | 1 |
| Shimada, M | 1 |
| Yoshikawa, K | 1 |
| Tokunaga, T | 1 |
| Nishi, M | 1 |
| Kashihara, H | 1 |
| Takasu, C | 1 |
| Wada, Y | 1 |
| Yoshimoto, T | 1 |
| Yamashita, S | 1 |
| Greenbaum, AM | 1 |
| Revollo, LD | 1 |
| Woloszynek, JR | 1 |
| Civitelli, R | 1 |
| Link, DC | 1 |
| Dosik, M | 1 |
| Kaufman, R | 1 |
3 other studies available for fluorouracil and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, M | 2022 |
N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells.
Topics: Animals; Base Sequence; Bone Diseases, Metabolic; Cadherins; Cell Lineage; Female; Fluorouracil; Gra | 2012 |
Raloxifene rebound regression.
Topics: Antineoplastic Agents; Bone Diseases, Metabolic; Breast Neoplasms; Carcinoma, Ductal; Cyclophosphami | 2004 |